Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
UBS
Healthtrust
Dow
Farmers Insurance
Queensland Health
Cantor Fitzgerald
Julphar
Citi

Generated: January 19, 2018

DrugPatentWatch Database Preview

HYPAQUE Drug Profile

« Back to Dashboard

When do Hypaque patents expire, and when can generic versions of Hypaque launch?

Hypaque is a drug marketed by Ge Healthcare and is included in five NDAs.

The generic ingredient in HYPAQUE is diatrizoate meglumine; diatrizoate sodium. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.

US Patents and Regulatory Information for HYPAQUE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare HYPAQUE diatrizoate sodium FOR SOLUTION;ORAL, RECTAL 011386-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ge Healthcare HYPAQUE SODIUM 20% diatrizoate sodium SOLUTION;URETERAL 009561-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ge Healthcare HYPAQUE diatrizoate sodium INJECTABLE;INJECTION 009561-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ge Healthcare HYPAQUE-76 diatrizoate meglumine; diatrizoate sodium INJECTABLE;INJECTION 086505-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ge Healthcare HYPAQUE diatrizoate sodium INJECTABLE;INJECTION 009561-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ge Healthcare HYPAQUE diatrizoate meglumine INJECTABLE;INJECTION 016403-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ge Healthcare HYPAQUE diatrizoate sodium SOLUTION;ORAL, RECTAL 011386-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ge Healthcare HYPAQUE diatrizoate meglumine INJECTABLE;INJECTION 016403-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ge Healthcare HYPAQUE-M,75% diatrizoate meglumine; diatrizoate sodium INJECTABLE;INJECTION 010220-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ge Healthcare HYPAQUE-M,90% diatrizoate meglumine; diatrizoate sodium INJECTABLE;INJECTION 010220-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
UBS
Express Scripts
Fish and Richardson
Novartis
Argus Health
McKinsey
QuintilesIMS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot